Journals / Medicine Science / 2019 / Cilt: 8 - Sayı: 1

Does augmentation with antipsychotic agents affect the medication adherence of the child with obsessive-compulsive disorder?

Pages
197–202
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our findings show the need for side-effects, and particularly psychological side-effects, the frequency of which increases with augmentation, to be monitored in terms of adherence to treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Antipsychotic agents can be used for augmentation when the response to treatment is insufficient in children with obsessive compulsive disorder.
📊
Key Findings & Data:One hundred fourteen children and adolescents aged 8-18 years diagnosed with OCD and still receiving treatment were included in the study.
💡
Conclusion & Impact:Our findings show the need for side-effects, and particularly psychological side-effects, the frequency of which increases with augmentation, to be monitored in terms of adherence to treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Antipsychotic agents can be used for augmentation when the response to treatment is insufficient in children with obsessive compulsive disorder. Our aim was to investigate adherence to treatment between patients with and without antipsychotic augmentation and factors potentially related to this. One hundred fourteen children and adolescents aged 8-18 years diagnosed with OCD and still receiving treatment were included in the study. Fifty-two subjects were received antipsychotic therapy for augmentation, while 62 were not receiving it. All subjects were evaluated using a sociodemographic data form, the 8-item Morisky Medication Adherence Scale (MMAS-8), and the Udvalg for Klinikse Undersegelser (UKU) side-effects rating scale. The results were then subjected to statistical analysis. Total MMAS-8 scores were statistically significantly lower in the augmentation group than in the monotherapy group (p: 0.01). Sex, receipt of psychotherapy and family monitoring of treatment had no effect on total MMAS-8 scores (p: 0.949, p: 0.394, and p: 0.198, respectively). Higher UKU side-effect rating scale scores were determined in the augmentation group compared to the monotherapy group (p<0.05). Correlation analysis revealed that UKU total score (r:-0.272, p:0.003) and UKU psychological side-effects subscale score (r:-0.263, p:0.005) were significantly inversely correlated with MMAS-8 total scores. Side-effects deriving from medications affected adherence to treatment more significantly than several other environmental factors in children with OCD. Our findings show the need for side-effects, and particularly psychological side-effects, the frequency of which increases with augmentation, to be monitored in terms of adherence to treatment.

🔖

Cite This Article

KARA, T., YILMAZ, S., KINAY, D., AKALTUN, İ. (2019). Does augmentation with antipsychotic agents affect the medication adherence of the child with obsessive-compulsive disorder?. Medicine Science, Cilt: 8 - Sayı: 1, 197–202. https://ajindex.com/articles/277127

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Rapoport JL, Shaw P. Obsessive compulsive disorder, in:Thapar A, Pine DS, Leckman JF, Scott S, Snowling MJ, Taylor E, editors. Rutter’s Child and Adolescent Psychiatry,Chichester, UK. John Wiley & Sons, Ltd, 2015. p. 841-857.
  2. Rapp AM, Bergman RL, Piacentini J, et al. Evidence-based assessment of obsessive-compulsive disorder. J Cent Nerv Syst Dis. 2016;8:13-29. Mendlowitz S. Cognitive-behavior therapy and the treatment of childhood obsessive-compulsive disorder, InRichard DCS,Lauterbach D, editors. Handbook of Exposure Therapies. Burlington, Academic Press, 2007. p. 20920. McGuire JF, Piacentini J, Lewin AB, et al. A meta-analysis of cognitive behavior therapy and medication for child obsessive compulsive disorder: moderators of treatment efficacy, response, and remission. Depress Anxiety. 2015;32:580-93.
  3. Bloch MH, Storch EA. Assessment and management of treatment-refractory obsessive-compulsive disorder in children. J Am Acad Child Adolesc Psychiatry. 2015;54:251-62.
  4. Seibell PJ, Hollander E.Management of obsessive-compulsive disorder. F1000 Prime Rep. 2014;6:68. Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am. 2014;37:375-91. Häge A, Weymann L, Bliznak L, et al. Non-adherence to psychotropic medication among adolescents -A systematic review of the literature. Z Kinder Jugendpsychiatr Psychother. 2016;44:1-10.
  5. Zullig LL, Mendys P, Bosworth HB. Medication adherence: A practical measurement selection guide using case studies.Patient Educ Couns. 2017;100:1410-4.
  6. Farooq S, Choudry A. Adherence to medication in the community: audit cycle of interventions to improve the assessment of adherence. BJPsych Bull. 2017;41:41-4.
  7. Bahrini L, Damak R, Cheour M. The role of the affective temperament in the treatment adherence in psychiatry. Pan Afr Med J. 2016;25:2. Winnick S, Lucas DO, Hartman AL, et al. How do you improve compliance? Pediatrics. 2005;115:718-24. Matsui DM. Drug compliance in pediatrics: clinical and research issues. Pediatr Clin North Am. 1997;44:1-14.
  8. Wade M, Tai S, Awenat Y, et al. A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis. Clin Psychol Rev. 2017;51:75-95.
  9. Geller, Daniel A, The AACAP Committee on Quality Issues (CQI). practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:98-113.
  10. Morisky DE, Ang A, Krousel-Wood M, et al.